AUPH Latest Press Releases

-- July 6, 2026 --

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis Business Wire 8:00 AM

-- June 4, 2026 --

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death Business Wire 7:00 AM

-- June 3, 2026 --

TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC. PRNewswire 12:44 AM

-- May 7, 2026 --

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress Business Wire 8:00 AM

-- March 30, 2026 --

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right Business Wire 8:00 AM

-- March 23, 2026 --

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition Business Wire 11:00 AM

Aurinia Announces Management Transition Business Wire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software